Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children

Autor: Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, Chaumey Rojas-Iriarte, Leyanis Céspedes-Henriquez, Misleidys Piedra-Bello, Dania Vega-Mendoza, Noelvia Pestana Pérez, Beatriz Paredes-Moreno, Meiby Rodríguez-González, Carmen Valenzuela-Silva, Belinda Sánchez-Ramírez, Laura Rodríguez-Noda, Rocmira Pérez-Nicado, Raul González-Mugica, Tays Hernández-García, Talía Fundora-Barrios, Martha Dubet Echevarría, Juliet María Enriquez-Puertas, Yenicet Infante-Hernández, Ariel Palenzuela-Díaz, Evelyn Gato-Orozco, Yanet Chappi-Estévez, Julio Cesar Francisco-Pérez, Miladi Suarez-Martinez, Ismavy C. Castillo-Quintana, Sonsire Fernandez-Castillo, Yanet Climent-Ruiz, Darielys Santana-Mederos, Yanelda García-Vega, María Eugenia Toledo-Romani, Delaram Doroud, Alireza Biglari, Yury Valdés-Balbín, Dagmar García-Rivera, Vicente Vérez-Bencomo, María Elena Mesa-Herrera, Yarmila García-Cristiá, Leonor Verdecia-Sánchez, Rafael del Valle Rodríguez, Yudalvies Oquendo-de la Cruz, Daysi Álvarez-Montalvo, Randy Grillo-Fortún, Liset López-González, Omaida Fonte Galindo, Yeseni Reyes-González, Ana Beatriz González-Álvarez, Linet Gorrita-Mora, Rodrigo Valera-Fernández, Ivis Ontivero-Pino, Marisel Martínez-Pérez, Esperanza Caballero-Gonzalez, Aniurka Garcés-Hechavarría, Dayle Martínez-Bedoya, Maite Medina-Nápoles, Yeney Regla Domínguez-Pentón, Yadira Cazañas-Quintana, Thais Fundora Barrios, Diana R. Hernández Fernández, Gretchen Bergado-Báez, Ivette Orosa-Vazquez, Franciscary Pi-Estopiñan, Marianniz Díaz-Hernández, Otto Cruz-Sui, Enrique Noa-Romero, Arilia García-López, Sandra Rivadereira Muro, Gerardo Baro-Roman

Publikováno v: International Journal of Infectious Diseases, Vol 126, Iss , Pp 164-173 (2023)

Objectives: To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o) combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods: A phase I/II open-label, adaptive, and multicenter trial evaluated the safet

Externí odkaz: https://doaj.org/article/88ee0659b0bf4cf3888a8d4fcd8fc08e

Importancia del pesquisaje de hepatitis virales en el diseño de estrategias de vacunación

Autor: Irina Valdivia, Rolando Ochoa, Janette Trujillo, Aurora Delahanty, Julio Ventura, Darién Ortega, Ariel Palenzuela, Carlos Silva

Publikováno v: VacciMonitor, Vol 14, Iss 2, Pp 1-6 (2005)

Se analiza de forma longitudinal la incidencia de hepatitis virales, así como las tasas de portadores del antígeno de superficie del virus de la hepatitis B (HBsAg) y de anticuerpos contra el virus de la hepatitis C, detectados en los programas de

Externí odkaz: https://doaj.org/article/71f0b3bb59914e4faaaccbf82d7635fe

Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial

Autor: Maria Eugenia-Toledo-Romani, Mayra García Carmenate, Leslyhana Verdecia-Sánchez, Suzel Pérez-Rodríguez, Meiby Rodriguez-González, Carmen Valenzuela-Silva, Beatriz Paredes-Moreno, Belinda Sánchez-Ramírez, Raul González-Mugica, Tays Hernández-García, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María Teresa Pérez-Guevara, Juliet Enríquez-Puertas, Enrique Noa-Romero, Ariel Palenzuela-Diaz, Gerardo Baro-Roman, Ivis Mendoza-Hernández, Yaima Muñoz, Yanet Gómez-Maceo, Bertha Leysi Santos Vega, Sonsire Fernandez-Castillo, Yanet Climent-Ruiz, Laura Rodríguez-Noda, Darielys Santana-Mederos, Yanelda García-Vega, Guang Wu-Chen, Delaram Doroud, Alireza Biglari, Tammy Boggiano-Ayo, Yury Valdés-Balbín, Daniel G. Rivera, Dagmar García-Rivera, Vicente Verez-Bencomo, SOBERANA Research Group

Publikováno v: SSRN Electronic Journal.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f09b7752aed724782cf3df97de63f4b9
https://doi.org/10.2139/ssrn.4023682

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme

Autor: Eduardo Ojito Magaz, Daniel G. Rivera, Ariel Palenzuela Diaz, Yanelda Garcia Vega, Leslihana Verdecia Sanchez, Tammy Boggiano Ayo, Meybis Rodriguez Gonzalez, Belinda Sánchez Ramírez, Anitza Fraga Quintero, Ivis Mendoza Hernandez, Yury Valdés Balbin, Franciscary Pi Estopinan, Guang-Wu Chen, Beatriz Perez Masson, Yanet Climent Ruiz, Sonsire Fernandez Castillo, Gretchen Bergado Báez, Otto Cruz Sui, Beatriz Paredes Moreno, Carmen Valenzuela Silva, Tays Hernandez Garcia, Gerardo Baro Roman, Dagmar García Rivera, Darielys Santana Mederos, Laura Rodriguez Noda, Vicente Verez Bencomo, Ubel Ramirez Gonzalez, Rocmira Perez Nicado, María Eugenia Toledo-Romaní, Raul Gonzalez Mugica, Majela Garcia Montero

BackgroundSOBERANA 02 is a COVID-19 conjugate vaccine candidate based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid. SOBERANA Plus antigen is dimeric-RBD. Here we report safety, reactogenicity and immunogenicity from phase I and IIa clin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::585980601f45319168ec11e934bb3723
https://doi.org/10.1101/2021.11.14.21266309

Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

Autor: María Eugenia Toledo-Romani, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez, Suzel Pérez-Rodríguez, Meybis Rodriguez-González, Carmen Valenzuela-Silva, Beatriz Paredes-Moreno, Belinda Sanchez-Ramirez, Raúl González-Mugica, Tays Hernández-Garcia, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María Teresa Pérez-Guevara, Juliet Enriquez-Puertas, Enrique Noa-Romero, Ariel Palenzuela-Diaz, Gerardo Baro-Roman, Ivis Mendoza-Hernández, Yaima Muñoz, Yanet Gómez-Maceo, Bertha Leysi Santos-Vega, Sonsire Fernandez-Castillo, Yanet Climent-Ruiz, Laura Rodríguez-Noda, Darielys Santana-Mederos, Yanelda García-Vega, Guang-Wu Chen, Delaram Doroud, Alireza Biglari, Tammy Boggiano-Ayo, Yury Valdés-Balbín, Daniel G. Rivera, Dagmar García-Rivera, Vicente Vérez-Bencomo, Mailin Cubas-Curbelo, Pedro Gabriel Rodríguez-Castillo, Yosmel Acevedo-Martínez, Solangel Estoque-Cabrera, José Alejandro Ávila-Cabreja, Ainadis Alfaro-Guzmán, Lilian Zulueta-Pérez, Niurka Tamara Espino-Rojas, Gloria Margarita Medinas-Santos, Ileana Luisa Sarda-Rodriguez, Mario Alejandro Acosta-Martinez, Radamet Reyes-Matienzo, José Manuel Coviella-Artime, Irania Morffi-Cinta, Marisel Martínez-Pérez, Rodrigo Valera-Fernández, Aniurka Garcés-Hechavarría, Dayle Martínez-Bedoya, Raine Garrido-Arteaga, Félix Cardoso-SanJorge, Ubel Ramírez-Gonzalez, Lauren Quintero-Moreno, Ivis Ontivero-Pino, Roselyn Martínez-Rivera, Berta Guillén-Obregón, Janet Lora-García, Maite Medina-Nápoles, Jennifer Espi-Ávila, Marcos Fontanies-Fernández, Yeney Regla Domínguez-Pentón, Gretchen Bergado-Baez, Franciscary Pi-Estopiñán, Eduardo Ojito-Magaz, Misladys Rodríguez, Otto Cruz-Sui, Majela García-Montero, Marta Dubed-Echevarría, Elena García-López, Evelyn Galano-Frutos, Alina Perez-Perez, Susana Morales-Ruano, Idalmis Brito-Pascual, Maité Amoroto, Amaylid Arteaga-García

Publikováno v: Med. 3:760-773.e5

SOBERANA 02 has been evaluated in phase I and IIa studies comparing homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we report results of immunogenicity, safety, and reactogenicity of SOBERANA 02 in a two- or three-d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d992db15fcafc31e61303944700136e9
https://doi.org/10.1016/j.medj.2022.08.001